JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals reported standalone revenue from operations of ₹1,03,990 lakhs in Q1 FY26, up about 9% from ₹95,231 lakhs in Q1 FY25. Standalone net profit after tax rose to ₹19,787 lakhs (vs ₹17,323 lakhs), a 14% jump, with basic EPS at ₹12.70. On a consolidated basis, revenue grew to ₹1,09,394 lakhs and PAT climbed to ₹20,238 lakhs, both up roughly 9% and 14% YoY respectively. The auditor (Deloitte Haskins & Sells LLP) issued an unmodified limited review report. The company also reiterated key details of the ongoing Torrent Pharmaceuticals deal: a share purchase agreement signed on June 29, 2025, an open offer to public shareholders, and a proposed amalgamation with a swap ratio of 51 Torrent shares for every 100 JB Chemicals shares.
The results show steady, mid-teens profit growth on the back of healthy revenue expansion, which is positive for shareholders. The pending Torrent takeover and merger scheme means shareholders' long-term return will largely depend on the open offer price and the share swap terms rather than standalone performance going forward.